Persistence of visual improvement one month after discontinuation of treatment · participants with acute CME (< 4 months) following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvement in leakage on FFA Â · participants with acute CME (< 4 months) following cataract surgery
It is very uncertain whether NSAID changes improvement in leakage on FFA Â compared with placebo or active control (very low certainty).
1 finding from 1 review
Improvement in central macular thickness on OCT · participants with acute CME (< 4 months) following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improved contrast sensitivity · participants with acute CME (< 4 months) following cataract surgery
It is very uncertain whether NSAID changes improved contrast sensitivity  compared with placebo or active control (very low certainty).
1 finding from 1 review
QoL · participants with acute CME (< 4 months) following cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Visual improvement at end of treatment, as defined by two or more Snellen lines · participants with chronic CME (≥ 4 months) following cataract surgery
It is very uncertain whether NSAID changes visual improvement at end of treatment, as defined by two or more… compared with placebo (very low certainty).
1 finding from 1 review
Persistence of visual improvement one month after discontinuation of treatment · participants with chronic CME (≥ 4 months) following cataract surgery
It is very uncertain whether NSAID changes persistence of visual improvement one month after discontinuation of… compared with placebo (very low certainty).
1 finding from 1 review
Improvement in leakage on FFA Â · participants with chronic CME (≥ 4 months) following cataract surgery
It is very uncertain whether NSAID changes improvement in leakage on FFA Â compared with placebo (very low certainty).
1 finding from 1 review
CAS improvement (decrease) by 2 or more points · thyroid‐associated ophthalmopathy
Summary of findings table ‐ Rituximab showed no clear difference in CAS improvement (decrease) by 2 or more points compared with intravenous methylprednisolone (low certainty).
1 finding from 1 review
Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with placebo (very low certainty).
1 finding from 1 review
Palpebral aperture change · thyroid‐associated ophthalmopathy
1 finding from 1 review
Motility · thyroid‐associated ophthalmopathy
1 finding from 1 review
Quality of life · thyroid‐associated ophthalmopathy
1 finding from 1 review
Adverse effects · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes adverse effects compared with placebo (very low certainty).
1 finding from 1 review
NOSPECS improvement (decrease) by 2 classes or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 or more classes compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Proptosis improvement (decrease) by 2 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes proptosis improvement (decrease) by 2 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Palpebral aperture improvement (decrease) by 3 mm or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes palpebral aperture improvement (decrease) by 3 mm or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Motility improvement (increase) by 1 class or more · thyroid‐associated ophthalmopathy
It is very uncertain whether summary of findings table ‐ Rituximab changes motility improvement (increase) by 1 class or more compared with intravenous methylprednisolone (very low certainty).
1 finding from 1 review
Quality of life improvement by at least 6 points · thyroid‐associated ophthalmopathy
1 finding from 1 review
Adverse events · thyroid‐associated ophthalmopathy
Summary of findings table ‐ Rituximab showed no clear difference in adverse events compared with intravenous methylprednisolone (low certainty).
1 finding from 1 review